Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
267
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation

Laura M. Roccograndia Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Alexandra R. Lovella Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0550-3868View further author information
ORCID Icon,
Alessandra Ferrajolib Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Philip A. Thompsonb Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jan A. Burgerb Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
William G. Wierdab Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Nitin Jainb Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Caitlin R. Rauscha Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-4166-5717View further author information
ORCID Icon show all
Pages 1554-1561 | Received 29 Dec 2022, Accepted 02 Jun 2023, Published online: 15 Jun 2023

References

  • National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic leukemia (Version 2.2023). 2023 [cited 2023 Jan 29]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
  • Imbruvica (ibrutinib) [package insert]. Sunnyvale (CA): Pharmacyclics, Inc.; 2020
  • Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–787. doi: 10.1038/leu.2014.247
  • Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–3995. doi: 10.1182/blood-2014-06-583294
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506. doi: 10.1182/blood-2014-10-606038
  • Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26(15):3918–3927. doi: 10.1158/1078-0432.CCR-19-2856
  • Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798. doi: 10.1038/s41375-019-0602-x
  • Fraser GAM, Chanan-Khan A, Demirkan F, et al. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2020;61(13):3188–3197 doi: 10.1080/10428194.2020.1795159.
  • Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;​6(11):3440–3450. doi: 10.1182/bloodadvances.2021006434
  • Thompson PA, Lévy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466. doi: 10.1111/bjh.14324
  • Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928. doi: 10.1182/blood.2019000840
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi: 10.1056/NEJMoa1306220
  • Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi: 10.1056/NEJMoa1915103
  • Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi: 10.1200/JCO.2018.78.8034
  • Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. doi: 10.1056/NEJMoa1711948
  • Raz MA, Arnason J, Bairey O, et al. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Br J Haematol. 2020;189(2):e31–e33. doi: 10.1111/bjh.16422
  • Kunk PR, Mock J, Devitt ME, et al. Major bleeding with ibrutinib: more than expected. Blood. 2016;128(22):3229–3229. doi: 10.1182/blood.V128.22.3229.3229
  • Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184(4):558–569. doi: 10.1111/bjh.15690

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.